Literature DB >> 15372210

Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals.

H Palmedo, J Bucerius.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15372210     DOI： 10.1007/s00259-004-1665-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Future directions for unsealed source radionuclide therapy for bone metastases.

Authors:  V R McCready; J M O'Sullivan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-16       Impact factor: 9.236

2.  Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities?

Authors:  Renato A Valdés Olmos; Cornelis A Hoefnagel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-23       Impact factor: 9.236

3.  A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Authors:  J H Turner; P G Claringbold
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

4.  Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.

Authors:  Holger Palmedo; Agnieska Manka-Waluch; Peter Albers; Ingo G H Schmidt-Wolf; Michael Reinhardt; Samer Ezziddin; Alexius Joe; Roland Roedel; Rolf Fimmers; F F Knapp; Stefan Guhlke; Hans-Jurgen Biersack
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544
  4 in total
  2 in total

1.  May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.

Authors:  Amir Sabet; Feras Khalaf; Soha Mahjoob; Abdullah Al-Zreiqat; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

2.  Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Authors:  Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif Alsharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 10.057
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.